Pacran is a branded cranberry supplement ingredient made from 100% whole cranberry fruit. Unlike many cranberry extracts that isolate a single compound, Pacran includes the juice, flesh, skin, and seeds of North American cranberries (Vaccinium macrocarpon), dried into a powder. It is manufactured by Givaudan-Naturex and marketed primarily for urinary tract health. You’ll find it listed on the labels of many UTI-focused supplements in capsule form, typically at a dose of 500 mg per day.
What Pacran Contains
Because Pacran is made from the whole fruit rather than a concentrated extract, it delivers a broad range of cranberry compounds rather than a high dose of any single one. The most studied of these are proanthocyanidins with type-A linkages (PACs), which are chains of plant compounds built from catechins and epicatechins. Pacran contains roughly 0.4% to 0.56% soluble PACs by weight, a figure that sounds small but reflects the natural concentration found in whole cranberries.
Beyond PACs, Pacran contains anthocyanins (the pigments that make cranberries red), flavonols, various phenolic acids, and organic acids like quinic acid, citric acid, and malic acid. It also provides soluble dietary fiber. The manufacturer’s argument is that these compounds work together rather than in isolation, and that focusing on PAC content alone misses the full picture of how cranberries affect urinary tract bacteria.
How It Works Against UTI Bacteria
Urinary tract infections are caused by uropathogenic E. coli in 70% to 90% of cases. These bacteria have hair-like structures on their surface called fimbriae, tipped with adhesins that latch onto the cells lining your bladder and urethra. Once attached, the bacteria colonize, multiply, and trigger infection.
The leading theory for how cranberry compounds help is anti-adhesion. Type-A proanthocyanidins appear to either bind directly to the bacteria’s fimbriae or alter their shape, making it harder for E. coli to grip onto bladder cells. If bacteria can’t attach, they get flushed out during urination before an infection takes hold. This is a preventive mechanism, not a treatment for an active infection. Cranberry metabolites produced during digestion may also contribute to this effect once they reach the urinary tract.
Clinical Evidence for UTI Prevention
The strongest evidence for Pacran comes from a 2025 multicenter, double-blind, placebo-controlled trial published in The American Journal of Clinical Nutrition. The study enrolled women with a history of recurrent UTIs and gave them either 500 mg of Pacran daily or a placebo for six months. The results were significant across several measures:
- Culture-confirmed UTIs dropped by 52% compared to placebo.
- UTIs with urgency and frequency symptoms dropped by 71%.
- E. coli-specific UTIs dropped by 51%.
- Total number of UTIs per participant fell by 59%.
Earlier trials used similar dosing in groups of 150 to 182 women over six-month periods, building the evidence base that led to the larger confirmatory study. The consistent finding is a meaningful reduction in UTI recurrence, particularly for women who experience multiple infections per year.
Pacran vs. Standard Cranberry Extracts
Many cranberry supplements on the market are formulated around a specific target: 36 mg of proanthocyanidins per dose, a threshold that originated from a health claim approved by French food safety authorities. These products typically use concentrated cranberry extracts designed to hit that PAC number.
Pacran takes a different approach. Its PAC content per 500 mg dose is only about 2 to 3 mg, far below the 36 mg benchmark. The manufacturer argues this comparison is misleading because PAC content alone doesn’t predict clinical effectiveness, and that the whole-fruit profile delivers benefits that isolated PAC fractions don’t. The European Food Safety Authority has noted, in reviewing various cranberry products, that product-specific clinical evidence matters more than hitting a particular PAC threshold. In practice, this means you should look for clinical trial data behind the specific ingredient in your supplement rather than choosing based on PAC milligrams alone.
Regulatory Status
Pacran does not carry an approved health claim in the European Union. EFSA reviewed the evidence and concluded that a cause-and-effect relationship between Pacran consumption and defense against urinary tract bacteria had not been established at the time of their review. This assessment predates the 2025 trial data. In the United States, Pacran is sold as a dietary supplement ingredient, which means it does not require FDA approval for efficacy claims. It can be marketed with structure/function claims (such as “supports urinary tract health”) but cannot claim to treat or prevent disease on its label.
Safety and Interactions
Cranberry products, including Pacran, are generally well tolerated at standard doses. The most common complaints are mild gastrointestinal discomfort. However, cranberry can interact with warfarin, a blood-thinning medication. Analysis of the available literature shows that large amounts of cranberry juice can destabilize warfarin therapy, though small amounts are not expected to cause problems. If you take warfarin or similar blood thinners, it’s worth discussing cranberry supplements with your prescriber, since even capsule forms deliver concentrated cranberry compounds.
Cranberry supplements, including Pacran, are not a substitute for antibiotics during an active UTI. Their role is preventive, reducing the likelihood that bacteria successfully colonize the urinary tract between infections. For women dealing with recurrent UTIs, a 500 mg daily dose taken consistently over months represents the usage pattern supported by clinical trials.